The Pfizer-BioNTech COVID-19 vaccine is less effective against the Omicron virus variant than other strains of the CCP virus, the companies said Wednesday, citing a study they ran. Scientists found on average a more than 25-fold reduction in neutralizing antibodies against the Omicron variant compared to the wild type, “indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant,” the companies said in a statement. BNT162b2 is another name for the vaccine. The CCP (Chinese Communist Party) virus causes COVID-19. Antibodies help protect people from COVID-19, along with T cells. Testing was done on samples of immune sera drawn from people who had received two or three doses of the vaccine. Most of the T cells triggered by the shot were not compromised by Omicron, according to the companies. That points to the shot holding up well against severe disease. Additionally, Pfizer and …